Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sedana Medical AB ( (SE:SEDANA) ) just unveiled an update.
Sedana Medical AB has announced the publication of its IsoCOMFORT paediatric study in The Lancet Respiratory Medicine, marking a significant achievement in paediatric critical care research. The study, which is the largest of its kind for inhaled isoflurane sedation, demonstrated the efficacy and safety of Sedaconda ACD in children aged 3-17, leading to paediatric approval in 13 European countries and extending market exclusivity until 2032. This development not only enhances Sedana Medical’s market position but also provides a significant clinical benefit over existing therapies, impacting stakeholders positively.
More about Sedana Medical AB
Sedana Medical AB is a pioneering medtech and pharmaceutical company specializing in inhaled sedation to enhance patient care during and after sedation. The company offers the Sedaconda ACD medical device and Sedaconda (isoflurane) pharmaceutical for mechanically ventilated patients in intensive care. Sedana Medical operates with direct sales in several European countries and partners with distributors in other global regions. Founded in 2005, it is listed on Nasdaq Stockholm and headquartered in Stockholm, Sweden.
Average Trading Volume: 333,355
Current Market Cap: SEK1.13B
Find detailed analytics on SEDANA stock on TipRanks’ Stock Analysis page.